Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
Rey-Búa B, Grande C, Sánchez Blanco JJ, Abrisqueta P, Gutiérrez A, Ramírez Páyer Á, Giné E, Zeberio Etxetxipia I, Terol MJ, de la Cruz Vicente F, Andreu R, Ramirez MJ, de la Fuente A, Viguria MC, Peñarrubia MJ, Jiménez-Ubieto A, Montes-Moreno S, López-Guillermo A, Caballero MD, Martín García-Sancho A. Rey-Búa B, et al. Among authors: abrisqueta p. Clin Cancer Res. 2024 Sep 3;30(17):3704-3714. doi: 10.1158/1078-0432.CCR-24-0183. Clin Cancer Res. 2024. PMID: 38900037 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 39112171
[No title available]
[No authors listed] [No authors listed] PMID: 39112190
[No title available]
[No authors listed] [No authors listed] PMID: 39112389
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment.
Iacoboni G, Navarro V, Sesques P, Rejeski K, Bastos-Oreiro M, Serpenti F, Martin Lopez AA, Iraola-Truchuelo J, Delgado J, Perez A, Guerreiro M, Caballero AC, Martinez-Cibrian N, Luzardo Henriquez H, Sanchez Pina JM, Sancho JM, Ghesquieres H, Mussetti A, Lopez Corral L, Hernani R, Reguera JL, Sureda A, Bosch F, Martin Garcia-Sancho A, Kwon M, Subklewe M, Kuhnl A, Bachy E, Barba P, Villacampa G, Abrisqueta P. Iacoboni G, et al. Among authors: abrisqueta p. J Hematol Oncol. 2024 Oct 29;17(1):102. doi: 10.1186/s13045-024-01608-8. J Hematol Oncol. 2024. PMID: 39468591 Free PMC article.
Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes.
Serna Á, Navarro V, Iacoboni G, López L, Sancho JM, González-Barca E, López-García A, Córdoba R, Sáez A, Ubieto AJ, Ferrero A, García T, Sánchez Á, García C, Bosch M, Cabirta A, Jiménez M, Marín-Niebla A, Bosch F, Abrisqueta P. Serna Á, et al. Among authors: abrisqueta p. Haematologica. 2025 Jan 1;110(1):173-178. doi: 10.3324/haematol.2024.285219. Haematologica. 2025. PMID: 38988269 Free PMC article. No abstract available.
Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
Abrisqueta P, González-Barca E, Ferrà C, Ríos-Herranz E, Fernández de la Mata M, Delgado J, Andreu R, Hernández-Rivas JÁ, Terol MJ, Navarro A, Vidriales MB, Baltasar P, De la Serna J, Ramírez Á, Ballester C, Moreno C, García-Marco JA, Córdoba R, Yáñez L, Casado LF, González M, Bosch F. Abrisqueta P, et al. EClinicalMedicine. 2024 May 25;73:102642. doi: 10.1016/j.eclinm.2024.102642. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 38841711 Free PMC article.
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.
Iacoboni G, Iraola-Truchuelo J, O'Reilly M, Navarro V, Menne T, Kwon M, Martín-López AÁ, Chaganti S, Delgado J, Roddie C, Pérez A, Norman J, Guerreiro M, Gibb A, Caballero AC, Besley C, Martínez-Cibrián N, Mussetti A, Sanderson R, Luzardo H, Iyengar S, Sánchez JM, Jones C, Sancho JM, Barba P, Latif AL, López-Corral L, Hernani R, Reguera JL, Sureda A, Garcia-Sancho AM, Bastos M, Abrisqueta P, Kuhnl A. Iacoboni G, et al. Among authors: abrisqueta p. Hemasphere. 2024 May 21;8(5):e62. doi: 10.1002/hem3.62. eCollection 2024 May. Hemasphere. 2024. PMID: 38774657 Free PMC article.
Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma.
Crochet G, Iacoboni G, Couturier A, Bachy E, Iraola-Truchuelo J, Gastinne T, Cartron G, Fradon T, Lesne B, Kwon M, Gounot R, Martínez-Cibrian N, Castilla-Llorente C, Abrisqueta P, Guerreiro M, Sarkozy C, Aspa-Cilleruelo JM, Camus V, Guidez S, Chauchet A, Deconinck E, Bouabdallah K, Bosch F, Barba P, Morschhauser F, Houot R. Crochet G, et al. Among authors: abrisqueta p. Blood. 2024 Jul 18;144(3):334-338. doi: 10.1182/blood.2024024526. Blood. 2024. PMID: 38657242 Free article.
New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
Bastos-Oreiro M, Abrisqueta P, Gutierrez A, Jiménez Ubieto A, Poza M, Fernanez-Caldas P, LLacer MJ, Gonzalez de Villambrosia S, Córdoba R, López A, Ceballos E, Navarro B, Muntañola A, Donato E, Diez-Baeza E, Escoda L, Luzardo H, Peñarrubia MJ, García Belmonte D, Pardal E, Lozada C, Martín García-Sancho A. Bastos-Oreiro M, et al. Among authors: abrisqueta p. Hemasphere. 2024 Apr 22;8(4):e70. doi: 10.1002/hem3.70. eCollection 2024 Apr. Hemasphere. 2024. PMID: 38650598 Free PMC article. No abstract available.
102 results